GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InterMune Inc (FRA:IUX) » Definitions » Cyclically Adjusted Book per Share

InterMune (FRA:IUX) Cyclically Adjusted Book per Share : €0.00 (As of Jun. 2014)


View and export this data going back to . Start your Free Trial

What is InterMune Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

InterMune's adjusted book value per share for the three months ended in Jun. 2014 was €2.318. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.00 for the trailing ten years ended in Jun. 2014.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-16), InterMune's current stock price is €58.06. InterMune's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2014 was €0.00. InterMune's Cyclically Adjusted PB Ratio of today is .


InterMune Cyclically Adjusted Book per Share Historical Data

The historical data trend for InterMune's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InterMune Cyclically Adjusted Book per Share Chart

InterMune Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

InterMune Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of InterMune's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, InterMune's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InterMune's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InterMune's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where InterMune's Cyclically Adjusted PB Ratio falls into.



InterMune Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, InterMune's adjusted Book Value per Share data for the three months ended in Jun. 2014 was:

Adj_Book= Book Value per Share /CPI of Jun. 2014 (Change)*Current CPI (Jun. 2014)
=2.318/100.5595*100.5595
=2.318

Current CPI (Jun. 2014) = 100.5595.

InterMune Quarterly Data

Book Value per Share CPI Adj_Book
200409 1.347 80.121 1.691
200412 0.781 80.290 0.978
200503 0.364 81.555 0.449
200506 -0.177 82.062 -0.217
200509 -0.771 83.876 -0.924
200512 0.826 83.032 1.000
200603 0.856 84.298 1.021
200606 -0.112 85.606 -0.132
200609 -0.689 85.606 -0.809
200612 -0.878 85.142 -1.037
200703 -1.211 86.640 -1.406
200706 -1.479 87.906 -1.692
200709 -0.258 87.964 -0.295
200712 -0.547 88.616 -0.621
200803 -0.926 90.090 -1.034
200806 -1.345 92.320 -1.465
200809 -1.644 92.307 -1.791
200812 -2.091 88.697 -2.371
200903 -1.540 89.744 -1.726
200906 -1.279 91.003 -1.413
200909 -1.259 91.120 -1.389
200912 -1.579 91.111 -1.743
201003 -0.302 91.821 -0.331
201006 -0.694 91.962 -0.759
201009 -0.940 92.162 -1.026
201012 1.348 92.474 1.466
201103 2.225 94.283 2.373
201106 1.937 95.235 2.045
201109 2.841 95.727 2.984
201112 2.331 95.213 2.462
201203 1.836 96.783 1.908
201206 1.979 96.819 2.055
201209 1.145 97.633 1.179
201212 0.619 96.871 0.643
201303 1.555 98.209 1.592
201306 1.298 98.518 1.325
201309 0.719 98.790 0.732
201312 0.991 98.326 1.014
201403 2.641 99.695 2.664
201406 2.318 100.560 2.318

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


InterMune  (FRA:IUX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


InterMune Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of InterMune's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


InterMune (FRA:IUX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InterMune Inc (FRA:IUX) » Definitions » Cyclically Adjusted Book per Share
Traded in Other Exchanges
N/A
Address
InterMune, Inc was incorporated in California in 1998 and reincorporated in Delaware in 2000 in connection with its initial public offering. InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. The Company's business is mainly focused on the development and commercialization of therapies within the specialized areas of pulmonology and orphan fibrotic diseases. It has an advanced-stage product candidate in pulmonology, pirfenidone that was granted marketing authorization effective February 2011 in all 27 member countries of the European Union for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is an orally active, small molecule compound under development for the treatment of idiopathic pulmonary fibrosis. Pirfenidone, a treatment for IPF, a progressive and fatal lung disease, has completed the global Phase 3 CAPACITY clinical development program. Actimmune is currently approved in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Actimmune is also approved for commercial use in both indications in numerous other countries. CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. Severe, malignant osteopetrosis is a life-threatening, congenital disorder that mainly affects children. This disease results in increased susceptibility to infection and an overgrowth of bony structures that might lead to blindness and/or deafness. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.

InterMune (FRA:IUX) Headlines

No Headlines